Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Low-Grade Glioma Market Size And Revenue Outlook Through 2030
The low-grade glioma market size has shown robust growth over recent years. It is anticipated to increase from $1.47 billion in 2025 to $1.56 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.9%. This past growth can be ascribed to advancements in neuroimaging technologies, enhanced survival rates in low-grade glioma patients, higher neurosurgical intervention rates, increasing awareness of brain tumor symptoms, and the expansion of oncology treatment centers.
The low-grade glioma market size is anticipated to experience substantial growth over the coming years. It is projected to expand to $1.94 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.6%. This expected growth throughout the forecast period stems from factors such as an increasing emphasis on molecular tumor profiling, greater investment in targeted oncology drugs, a growing demand for less aggressive treatment options, expanding availability of specialized neuro-oncology care, and ongoing clinical trials for new therapies. Furthermore, significant trends during this period include a heightened focus on early diagnosis and monitoring, a growing uptake of targeted drug therapies, an increasing preference for multimodal treatment approaches, the expansion of personalized treatment planning, and the rise of long-term disease management strategies.
Get A Free Sample Report With In-Depth Market Insights:
Low-Grade Glioma Market Industry Drivers: What’s Behind The Revenue Growth?
The rising prevalence of brain tumors is anticipated to drive the expansion of the low-grade glioma market. A brain tumor is characterized as an unusual proliferation of cells in or around the brain, which can be either non-cancerous or cancerous. The increasing occurrence of brain tumors is attributed to factors such as greater exposure to radiation, environmental pollutants, genetic susceptibilities, and advancing age. Low-grade glioma interventions are beneficial for brain tumors by utilizing advanced diagnostic methods and targeted treatments like surgery, radiation, and chemotherapy. These approaches contribute to decelerating tumor growth, preserving neurological capabilities, and enhancing patient prognosis, making prompt detection and personalized care essential for managing other brain tumors with comparable growth patterns. For instance, in October 2025, according to the Cancer Australia, an Australia-based government agency, in 2023, Australia recorded 1,597 deaths from brain cancer (956 men and 641 women). By 2025, this number is expected to rise slightly to 1,639 deaths (979 men and 660 women). The estimated risk of dying from brain cancer by age 85 in 2025 is 1 in 195 (0.51%), with the risk higher for males at 1 in 165 (0.61%) and lower for females at 1 in 240 (0.42%). Therefore, the increasing incidence of brain tumors is a key driver for the growth of the low-grade glioma market.
Low-Grade Glioma Market Segment Landscape: Which Areas Lead Development?
The low-grade glioma market covered in this report is segmented –
1) By Drug Type: Trametinib, Dabrafenib, Ivosidenib, Mirdametinib
2) By Treatment: Surgery, Chemotherapy, Radiation
3) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies
Subsegments:
1) By Trametinib: MEK Inhibitor Monotherapy, Combination Therapy (with BRAF Inhibitors)
2) By Dabrafenib: BRAF V600E–Mutant Low-Grade Glioma, Combination Therapy (with MEK Inhibitors)
3) By Ivosidenib: IDH1-Mutant Low-Grade Glioma, Oral Targeted Monotherapy
4) By Mirdametinib: NF1-Associated Low-Grade Glioma, MEK Inhibitor Monotherapy
#Low-Grade Glioma Market Growth Trends: What’s Shaping The Future Outlook?
Leading firms within the low-grade glioma market are prioritizing the integration of combination therapies and targeted treatments, such as genetic alteration drugs, to secure a competitive advantage and enhance care for children with low-grade glioma. Genetic alteration drugs are targeted therapies developed to modify or inhibit specific genetic mutations or abnormalities within cells, thereby assisting in treating diseases like cancer by blocking the pathways responsible for uncontrolled cell growth. For instance, in May 2024, Day One Biopharmaceuticals, a US-based biotechnology company, introduced Tovorafenib (Ojemda) after securing accelerated FDA approval. This targeted therapy is intended for children aged six months and older presenting with unresectable or recurrent low-grade glioma (LGG) linked to BRAF gene alterations. Providing a convenient once-weekly oral treatment, it addresses a critical requirement for pediatric LGG patients who have had limited prior treatment options.
Low-Grade Glioma Market Industry Leaders And Competitive Landscape
Major companies operating in the low-grade glioma market are F Hoffmann La Roche Ltd, Novartis AG, AstraZeneca PLC, Bristol Myers Squibb Company, Merck & Co Inc, Ipsen SA, Agios Pharmaceuticals Inc, Day One Biopharmaceuticals Inc, Les Laboratoires Servier, BeiGene Ltd, Daiichi Sankyo Company Limited, AnHeart Therapeutics Inc, Apollomics Inc, CStone Pharmaceuticals Co Ltd, Avistone Biotechnology Co Ltd, Blueprint Medicines Corporation, Revolution Medicines Inc, SpringWorks Therapeutics Inc, Exelixis Inc, Genentech Inc
View The Full Low-Grade Glioma Market Report:
Low-Grade Glioma Market Regional Breakdown: Where Is Demand Concentrated?
North America was the largest region in the low-grade glioma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low-grade glioma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
